Normalization of elevated liver enzymes due to V-1 Immunitor therapy

• Vichai Jirathitikal ^[1] ; Orapun Metadilogkul ^[2] ; Aldar S. Bourinbaiar ^[1]
  1. [1] Immunitor Corporation Co., Ltd.
  2. [2] The Ministry of Public Health Rajavithi General Hospital Occupational and Environmental Medicine Association of Thailand
• Localización: Electronic Journal of Biotechnology, ISSN-e 0717-3458, Vol. 6, Nº. 1, 2003, págs. 5-6
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • V-1 Immunitor (V1) is an oral AIDS vaccine currently being used as a therapeutic modality by HIV-positive patients. Upon interim analysis of phase I safety trial it has been discovered that patients who had elevated liver enzymes aspartate (AST/SGOT) and alanine (ALT/SGPT) aminotransferases have experienced the reduction of enzyme levels back to normal. Two other hepatitis markers alkaline phosphatase and bilirubin have also decreased. V1’s effect may be hepatitis-specific since liver enzymes in normal patients treated with V1 have not changed and three patients who were Hepatitis B antigen positive at baseline became negative after therapy. The results suggest that V1 supplementation reduces hepatic damage caused by hepatitis viral infection.